Active, not recruitingPhase 3NCT04691154
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Studying Heritable pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Liquidia Technologies, Inc.
- Intervention
- L606 inhalation suspension(combination_product)
- Enrollment
- 28 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2021 – 2031
Study locations (8)
- Arizona Pulmonary Specialists, Scottsdale, Arizona, United States
- VA Greater Los Angeles Healthcare, Los Angeles, California, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- University of Cincinnati Medical Center, Cincinnati, Ohio, United States
- Summit Health Eastside Clinic, Bend, Oregon, United States
- Baylor Scott and White Research Institute, Temple, Texas, United States
Collaborators
PPD Development, LP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04691154 on ClinicalTrials.govOther trials for Heritable pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07498244Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) PatientsMedical University of Graz
- RECRUITINGNANCT07079592A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary HypertensionNational Defense Medical Center, Taiwan
- RECRUITINGPHASE4NCT07147114Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)Gachon University Gil Medical Center
- RECRUITINGPHASE2NCT07073820A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489Pfizer
- RECRUITINGNCT07537517Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.Hospital General Universitario Gregorio Marañon
- RECRUITINGNANCT07120789Validation of a Patient Knowledge Questionnaire for Pulmonary HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNANCT07576894Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary DiseaseUniversity of Colorado, Denver
- RECRUITINGNCT07087613Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECGEko Devices, Inc.
See all trials for Heritable pulmonary arterial hypertension →